A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy
Journal of Liver Cancer
; : 88-93, 2017.
Artigo
em Coreano
| WPRIM (Pacífico Ocidental)
| ID: wpr-156763
Biblioteca responsável:
WPRO
ABSTRACT
Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under 3 months is far from clinical satisfactory and most patients experience disease progression within 6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment failure of sorafenib was not established and there were no clear guidelines for salvage treatment modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent can be relatively effective and safe strategy that achieves promising rates of local and systemic control in advanced HCC patients. Based on above suggestions, we herein offer our experience of a case achieved complete remission by combination therapy of sorafenib and tegafur in the patient with progressed disease after sorafenib therapy.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Tegafur
/
Terapia de Salvação
/
Falha de Tratamento
/
Carcinoma Hepatocelular
/
Progressão da Doença
Tipo de estudo:
Guia de prática clínica
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Liver Cancer
Ano de publicação:
2017
Tipo de documento:
Artigo